stoxline Quote Chart Rank Option Currency Glossary
  
Abcam plc (ABCM)
23.99  0.01 (0.04%)    12-05 16:00
Open: 23.99
High: 24
Volume: 7,430,229
  
Pre. Close: 23.98
Low: 23.98
Market Cap: 5,521(M)
Technical analysis
2024-01-12 4:49:09 PM
Short term     
Mid term     
Targets 6-month :  28.03 1-year :  32.74
Resists First :  24 Second :  28.03
Pivot price 23.97
Supports First :  23.4 Second :  23.04
MAs MA(5) :  23.98 MA(20) :  23.96
MA(100) :  23.02 MA(250) :  19.37
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  86.3 D(3) :  86.9
RSI RSI(14): 73.1
52-week High :  25.31 Low :  12.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ABCM ] has closed below upper band by 33.0%. Bollinger Bands are 93.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 24.05 - 24.16 24.16 - 24.26
Low: 23.65 - 23.82 23.82 - 23.95
Close: 23.76 - 24.01 24.01 - 24.21
Company Description

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Headline News

Thu, 23 May 2024
ABCAM PLC First Half Trading Update - The Globe and Mail

Thu, 23 May 2024
Abcam plc: Update on AIM Delisting - The Globe and Mail

Thu, 23 May 2024
Is Abcam (ABCM) Outperforming Other Medical Stocks This Year? - Yahoo New Zealand News

Tue, 21 May 2024
GMED or ABCM: Which Is the Better Value Stock Right Now? - Yahoo Movies UK

Fri, 17 Nov 2023
Abcam Acquisition by Danaher has Received all Identified Clearances; Transaction Expected to Close on December 6 ... - Abcam plc

Mon, 06 Nov 2023
Shareholders of Abcam Approve Proposed Acquisition by Danaher – Abcam Limited - Abcam plc

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 230 (M)
Shares Float 192 (M)
Held by Insiders 6.4 (%)
Held by Institutions 88.2 (%)
Shares Short 4,080 (K)
Shares Short P.Month 2,900 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.14
Profit Margin 0.6 %
Operating Margin 18.3 %
Return on Assets (ttm) 4.3 %
Return on Equity (ttm) 0.3 %
Qtrly Rev. Growth 9.6 %
Gross Profit (p.s.) 0
Sales Per Share 1.64
EBITDA (p.s.) 0.46
Qtrly Earnings Growth 188 %
Operating Cash Flow 26 (M)
Levered Free Cash Flow 29 (M)
Stock Valuations
PE Ratio 2399
PEG Ratio 0
Price to Book value 7.64
Price to Sales 14.54
Price to Cash Flow 210.73
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android